Am J Respir Crit Care Med:COPD药物治疗对心肺血管和功能都有有利影响

2015-11-14 phylis 译 MedSci原创

基本原理:慢性阻塞性肺疾病患者因结构改变可增加心血管疾病的发病。目标:这项双盲,安慰剂对照,交叉研究探讨肺收缩对心血管结构和功能的影响,应用心脏磁共振检查肺的心血管结构和功能。方法:45个慢性阻塞性肺疾病患者随机(1:1)到7天(最大14天)吸入糖皮质激素/长效β2-受体激动剂糠酸氟替卡松/维兰特罗100 / 25μg或安慰剂(7天)。主要预后:与安慰剂相比,右心室舒张末期容积指数的变化。主要结果

基本原理:慢性阻塞性肺疾病患者因结构改变可增加心血管疾病的发病。

目标:这项双盲、安慰剂对照、交叉研究探讨肺收缩对心血管结构和功能的影响,应用心脏磁共振检查肺的心血管结构和功能。

方法:45个慢性阻塞性肺疾病患者随机(1:1)到7天(最大14天)吸入糖皮质激素/长效β2-受体激动剂糠酸氟替卡松/维兰特罗100 / 25μg或安慰剂(7天)。

主要预后:与安慰剂相比,右心室舒张末期容积指数的变化。

主要结果:基线右室舒张末期容积指数变化增加了5.8mL/m2(95%CI 2.74-8.91),与安慰剂相比,糠酸氟替卡松/维兰特罗治疗组患者残余量下降了 429mL;。左室舒张末期和左心房收缩末期容积增加3.63mL/m2、2.33mL/m2。在post-poc分析中,右心室搏出量增加了4.87 mL/m2,右室射血分数不变。左室顺应性没有差异;左心房射血分数提高3.17%。心肌功能没有变化。在2/3的位置的肺动脉搏动增强(主+ 2.9%;左+ 2.67%)。糠酸氟替卡松/维兰特罗的安全性与安慰剂组相似。

结论:慢性阻塞性肺疾病的药物治疗对心脏功能和肺血管的有益影响是一致的,这有助于吸入疗法的有利影响。需要进一步的研究探讨长期的肺收缩对固有心肌功能的影响。

原文出处:

Stone IS, Barnes NC, James WY, et al.  Lung Deflation and Cardiovascular Structure and Function in COPD: A Randomized Controlled Trial. Am J Respir Crit Care Med. 2015, Nov 9.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=111872, encodeId=e31c1118e220, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=111873, encodeId=ede61118e387, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684411, encodeId=cd5e1684411df, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Tue Feb 23 02:10:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43610, encodeId=edf143610db, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 01:35:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43279, encodeId=4461432e90c, content=可以理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:52:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545503, encodeId=df4015455031e, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606711, encodeId=5a761606e1145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2016-09-05 doctorJiangchao

    继续学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=111872, encodeId=e31c1118e220, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=111873, encodeId=ede61118e387, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684411, encodeId=cd5e1684411df, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Tue Feb 23 02:10:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43610, encodeId=edf143610db, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 01:35:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43279, encodeId=4461432e90c, content=可以理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:52:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545503, encodeId=df4015455031e, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606711, encodeId=5a761606e1145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2016-09-05 doctorJiangchao

    继续关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=111872, encodeId=e31c1118e220, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=111873, encodeId=ede61118e387, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684411, encodeId=cd5e1684411df, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Tue Feb 23 02:10:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43610, encodeId=edf143610db, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 01:35:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43279, encodeId=4461432e90c, content=可以理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:52:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545503, encodeId=df4015455031e, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606711, encodeId=5a761606e1145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2016-02-23 aids222
  4. [GetPortalCommentsPageByObjectIdResponse(id=111872, encodeId=e31c1118e220, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=111873, encodeId=ede61118e387, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684411, encodeId=cd5e1684411df, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Tue Feb 23 02:10:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43610, encodeId=edf143610db, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 01:35:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43279, encodeId=4461432e90c, content=可以理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:52:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545503, encodeId=df4015455031e, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606711, encodeId=5a761606e1145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2015-11-24 owlhealth

    挺好的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=111872, encodeId=e31c1118e220, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=111873, encodeId=ede61118e387, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684411, encodeId=cd5e1684411df, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Tue Feb 23 02:10:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43610, encodeId=edf143610db, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 01:35:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43279, encodeId=4461432e90c, content=可以理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:52:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545503, encodeId=df4015455031e, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606711, encodeId=5a761606e1145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
    2015-11-16 lixh1719

    可以理解

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=111872, encodeId=e31c1118e220, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=111873, encodeId=ede61118e387, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684411, encodeId=cd5e1684411df, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Tue Feb 23 02:10:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43610, encodeId=edf143610db, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 01:35:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43279, encodeId=4461432e90c, content=可以理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:52:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545503, encodeId=df4015455031e, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606711, encodeId=5a761606e1145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=111872, encodeId=e31c1118e220, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=111873, encodeId=ede61118e387, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Sep 05 23:17:00 CST 2016, time=2016-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684411, encodeId=cd5e1684411df, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Tue Feb 23 02:10:00 CST 2016, time=2016-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43610, encodeId=edf143610db, content=挺好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Tue Nov 24 01:35:00 CST 2015, time=2015-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43279, encodeId=4461432e90c, content=可以理解, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Mon Nov 16 14:52:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545503, encodeId=df4015455031e, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606711, encodeId=5a761606e1145, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=13, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 16 09:10:00 CST 2015, time=2015-11-16, status=1, ipAttribution=)]

相关资讯

Sci Rep:COPD患者应用他汀类药物,死亡率显著下降

研究旨在评估使用他汀类药物是否与慢性阻塞性肺病患者的良好预后相关。研究者对所有描述应用他汀类药物和COPD患者死亡率,恶化及心血管事件的发生的研究进行了一项系统综述和meta分析。搜索了MEDLINE,EMBASE,Web of Science,和Cochrane对照试验注册中心数据库。评估了HR值及95%CI。一共纳入15个研究,238459名受试者。九篇文章中提供了各种原因的死亡数据(1245

Psychoneuroendocr:临床早期诊断COPD患者抑郁的简便方法:检测促炎性因子和皮质醇水平

在全球范围内,COPD是导致慢性发病率和死亡率的主要原因。在中国,超过4千万人患有COPD,每年的死亡率超过128万。抑郁在COPD患者中十分常见,其会加速疾病的恶化和增加治疗费用。研究发现,抑郁与HPA轴的功能紊乱和促炎性因子有关。而COPD是以系统性炎症反应为特征的疾病,患者的促炎性因子(如IL-1、IL-6和TNF-α)水平升高,而且这些炎性因子会激活HPA轴。然而,关于COPD患者的抑郁与

NEJM:FEV1的加速下降并不是慢性阻塞性肺疾病的专性特征

慢性阻塞性肺疾病(COPD)被认为是1秒内用力呼气量(FEV1)迅速下降的结果。然而,也有可能在那些最大限度地获得FEV1也低于正常人群的患者中,FEV1一个正常的下降也可能导致慢性阻塞性肺病。     研究人员根据在队列开始(平均年龄患者中,约40岁)时的肺功能(FEV1≥80%或<80%的预测值)和最后一次研究拜访存在或不存在的COPD,在三个独立

PLoS One:慢性阻塞性肺疾病患者的聚类分析

背景: 我们假设慢性阻塞性肺疾病的全球倡议(GOLD)1肺活量的类别存在异质性,不同的子类别可以通过GOLD类别进行确定。方法: 来自两个临床试验预-随机化研究的受试者为有症状/无症状GOLD 1慢性阻塞性肺疾病(COPD)患者和健康对照组。层次聚类分析使用预-随机化人口统计,症状评分、肺功能、运动响应峰值和日常身体活动水平获得人群子组。结果: GOLD 1慢性阻塞性肺疾病患者临床变量存在相当大的

Am J Respir Crit Care Med:COPD可增加卒中风险,抽烟是两者共同的危险因素

背景:慢性阻塞性肺疾病(COPD)和卒中是世界上最主要的死因。有证据证明这两种疾病存在相关性,COPD患者由动脉粥样硬化风险增加引起,或者卒中和COPD有共同的危险因子。目的:为了调查一般人群中COPD和卒中个亚型的相关性,并且探索心血管危险因素的作用,是否增加这种相关性。方法:前瞻性基于群体的鹿特丹研究中,研究者随访了13115名物卒中史的受试者。随访从1990-2008年开始,2012年结束。

Lancet:比较GOLD 2007和2011预测慢性阻塞性肺疾病死亡率

背景:慢性阻塞性肺疾病(COPD)的最佳分期系统上没有达成普遍共识。虽然文件(例如,慢性阻塞性肺疾病2007年全球倡议[GOLD])传统上使用1秒用力呼气容积(FEV1)分期,临床参数已被添加到一些准则中(如GOLD 2011),以改善患者管理。作为COPD国际合作评估(3CIA)计划的一部分,该研究的目的是调查患者如何通过GOLD 2007和2011进行了分类,并比较临时文件的死亡率的预测准确性